SEC Form 4
Exelixis Inc (EXEL) insider trading
In the 12 months to Oct 24, 2026, 12 EXEL insiders reported open-market sales of $42.2M across 23 filings; one director bought $1.2M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $42.2M
- 23 filings · 12 insiders
- Open-market purchases
- $1.2M
- 1 filing · David Edward Johnson, Director
- Pre-arranged sales (10b5-1)
- 7 of 23
- $6.9M of $42.2M sold (16%)
Who traded EXEL, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
EXEL daily close from Oct 24, 2025 to Oct 23, 2026, between $37.90 and $65.31, last $64.53. 23 sale and 1 purchase filings by 13 insiders, marked at their filing dates. Dana Aftab, EVP, Research and Development: sold $7.7M across 4 filings, first filed Nov 13, 2025, last May 28, 2026. Patrick J. Haley, EVP, Commercial: sold $7.6M across 3 filings, first filed Nov 24, 2025, last May 22, 2026. Julie Smith, Director: sold $4.7M across 1 filing, first filed Feb 19, 2026, last Feb 19, 2026. Jack L. Wyszomierski, Director: sold $4.6M across 2 filings, first filed Feb 20, 2026, last Jun 3, 2026. Christopher J. Senner, EVP and CFO: sold $4.6M across 2 filings, first filed Feb 18, 2026, last May 19, 2026. Stelios Papadopoulos, Director: sold $4.4M across 1 filing, first filed Nov 13, 2025, last Nov 13, 2025. David Edward Johnson, Director: bought $1.2M across 1 filing, first filed Nov 26, 2025, last Nov 26, 2025. 6 others: sold $8.8M across 10 filings, first filed Nov 13, 2025, last Aug 12, 2026.
Largest mark · tap a row for others
Julie Smith · Director
Sale $4,687,346
106,539 shares at $44.00 avg
Filed Feb 19, 2026 · traded Feb 17
Close on filing date $44.16
Dana Aftab · EVP, Research and Development
EVP, Research and Development
$7.7M soldPatrick J. Haley · EVP, Commercial
EVP, Commercial
$7.6M soldJulie Smith · Director
Director
$4.7M soldJack L. Wyszomierski · Director
Director
$4.6M soldChristopher J. Senner · EVP and CFO
EVP and CFO
$4.6M soldStelios Papadopoulos · Director
Director
$4.4M soldDavid Edward Johnson · Director
Director
$1.2M bought6 others
Combined, one mark per week
$8.8M soldHas Exelixis Inc's CEO sold stock?
No. Michael Morrissey (CEO) made no open-market sales filed as CEO in the last 12 months.
Open-market trades
24 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Dana Aftab | EVP, Research and Development | $7.7M | — | 4 | — | |
| Patrick J. Haley | EVP, Commercial | $7.6M | — | 3 | — | |
| Julie Smith | Director | $4.7M | — | 1 | — | |
| Jack L. Wyszomierski | Director | $4.6M | — | 2 | 100% of sales | |
| Christopher J. Senner | EVP and CFO | $4.6M | — | 2 | — | |
| Stelios Papadopoulos | Director | $4.4M | — | 1 | — | |
| George Poste | Director | $2.7M | — | 1 | — | |
| Mary C. Beckerle | Director | $1.9M | — | 3 | 27% of sales | |
| Bob Oliver | Director | $1.3M | — | 1 | — | |
| David Edward Johnson | Director | — | $1.2M | 1 | — | |
| Brenda Hefti | SVP and General Counsel | $1.2M | — | 2 | 100% of sales | |
| Maria C. Freire | Director | $949.2K | — | 1 | — | |
| Sue Gail Eckhardt | Director | $660.8K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Mary C. Beckerle Director | SalePre-arranged (10b5-1) | 9,812 | $53.66 | $526.5K | 16,079 | |
traded | Sue Gail Eckhardt Director | SalePre-arranged (10b5-1) | 9,812 | $50.14 | $492.0K | 16,079 | |
traded | Jack L. Wyszomierski Director | SalePre-arranged (10b5-1) | 3,925 | $50.55 | $198.4K | 284,384 | |
traded | Dana Aftab EVP, Research and Development | Sale | 43,451 | $50.35 | $2.2M | 594,741 | |
traded | Patrick J. Haley EVP, Commercial | Sale | 32,110 | $49.81 | $1.6M | 357,638 | |
traded | Brenda Hefti SVP and General Counsel | SalePre-arranged (10b5-1) | 6,625 | $50.21 | $332.6K | 106,762 | |
traded | Christopher J. Senner EVP and CFO | Sale | 34,901 | $50.00 | $1.7M | 952,317 | |
traded | George Poste Director | Sale | 60,000 | $45.71 | $2.7M | 118,832 | |
traded | Maria C. Freire Director | Sale | 20,634 | $46.00 | $949.2K | 100,819 | |
traded | Mary C. Beckerle Director | Sale | 7,712 | $48.45 | $373.6K | 17,524 | |
traded | Dana Aftab EVP, Research and Development | Sale | 47,918 | $44.50 | $2.1M | 616,106 | |
traded | Dana Aftab EVP, Research and Development | Sale | 29,873 | $44.35 | $1.3M | 664,024 | |
traded | Jack L. Wyszomierski Director | SalePre-arranged (10b5-1) | 99,574 | $44.01 | $4.4M | 279,942 | |
traded | Julie Smith Director | Sale | 106,539 | $44.00 | $4.7M | 20,590 | |
traded | Brenda Hefti SVP and General Counsel | SalePre-arranged (10b5-1) | 18,669 | $44.01 | $821.6K | 96,512 | |
traded | Bob Oliver Director | Sale | 30,250 | $43.81 | $1.3M | 21,120 | |
traded | Sue Gail Eckhardt Director | SalePre-arranged (10b5-1) | 3,856 | $43.79 | $168.9K | 17,524 | |
traded | Patrick J. Haley EVP, Commercial | Sale | 67,814 | $43.52 | $3.0M | 446,686 | |
traded | Christopher J. Senner EVP and CFO | Sale | 64,895 | $43.32 | $2.8M | 976,092 | |
traded | David Edward Johnson Director | Purchase | 27,532 | $43.12 | $1.2M | 1,553,262 | |
traded | Patrick J. Haley EVP, Commercial | Sale | 72,230 | $42.18 | $3.0M | Multiple accounts | |
traded | Mary C. Beckerle Director | Sale | 24,622 | $41.93 | $1.0M | 21,380 | |
traded | Dana Aftab EVP, Research and Development | Sale | 48,383 | $42.50 | $2.1M | 664,778 | |
traded | Stelios Papadopoulos Director | Sale | 100,000 | $43.55 | $4.4M | 1,189,228 |
GET /stocks/filings/vX/form-4?tickers=EXEL&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"EXEL"
],
"issuer_cik": "0000939767",
"owner_cik": "0001520181",
"accession_number": "0000939767-26-000101",
"form_type": "4",
"filing_date": "2026-08-12",
"period_of_report": "2026-08-10",
"issuer_name": "EXELIXIS, INC.",
"issuer_trading_symbol": "EXEL",
"owner_name": "Beckerle Mary C",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-10",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9812,
"transaction_price_per_share": 53.66,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 16079,
"transaction_value": 526511.9199999999,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026."
},
{
"id": "F2",
"description": "Represents the weighted average sales price. The shares of Exelixis, Inc. common stock (\"Common Stock\") were sold in multiple transactions at prices ranging from $53.16 to $54.02. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4."
},
{
"id": "F3",
"description": "Includes 16,079 shares of Common Stock that will be issued to the Reporting Person upon vesting of restricted stock units (\"RSUs\"). Each RSU is the economic equivalent of one share of Common Stock."
}
]
},
{
"tickers": [
"EXEL"
],
"issuer_cik": "0000939767",
"owner_cik": "0001823769",
"accession_number": "0000939767-26-000084",
"form_type": "4",
"filing_date": "2026-06-03",
"period_of_report": "2026-06-01",
"issuer_name": "EXELIXIS, INC.",
"issuer_trading_symbol": "EXEL",
"owner_name": "Eckhardt Sue Gail",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9812,
"transaction_price_per_share": 50.14,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 16079,
"transaction_value": 491973.68,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2025."
},
{
"id": "F2",
"description": "Represents the weighted average sales price. The shares of Exelixis, Inc. common Stock (\"Common Stock\") were sold in multiple transactions at prices ranging from $49.73 to $50.61. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4."
},
{
"id": "F3",
"description": "Includes 16,079 shares of Common Stock that will be issued to the Reporting Person upon vesting of restricted stock units (\"RSUs\"). Each RSU is the economic equivalent of one share of Common Stock."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 58 records
- Option exercises9 records
- Tax withholding16 records
- Grants and awards19 records
- Gifts14 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for EXEL every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.